I-Mab (DB:0VY) - Stock Price, News & Analysis

0VY Stock Overview

A clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States.

About the company

0VY fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 29.33% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue (CN¥28M)

Volatile share price over the past 3 months

I-Mab Competitors

Heidelberg Pharma

XTRA:HPHA

€121.6m

Medigene

XTRA:MDG1

€34.8m

2invest

XTRA:2INV

€54.0m

Biotest

XTRA:BIO3

€1.4b

Price History & Performance

Summary of all time highs, changes and price drops for I-Mab
Historical stock prices
Current Share Price	US$1.41
52 Week High	US$2.68
52 Week Low	US$1.09
Beta	1.08
11 Month Change	-1.40%
3 Month Change	-14.02%
1 Year Change	-44.92%
33 Year Change	-97.73%
5 Year Change	n/a
Change since IPO	-87.84%

Recent updates

Shareholder Returns

	0VY	DE Biotechs	DE Market
7D	-10.2%	1.2%	0.8%
1Y	-44.9%	-16.0%	6.1%

Return vs Industry: 0VY underperformed the German Biotechs industry which returned -16% over the past year.

Return vs Market: 0VY underperformed the German Market which returned 6.1% over the past year.

Price Volatility

Is 0VY's price volatile compared to industry and market?
0VY volatility
0VY Average Weekly Movement	7.6%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.7%
10% most volatile stocks in DE Market	10.5%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 0VY has not had significant price volatility in the past 3 months.

Volatility Over Time: 0VY's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2014	220	Raj Kannan	ir.i-mabbiopharma.com

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy.

I-Mab Fundamentals Summary

How do I-Mab's earnings and revenue compare to its market cap?
0VY fundamental statistics
Market cap	€111.95m
Earnings (TTM)	-€186.50m
Revenue (TTM)	€3.52m

31.8x

P/S Ratio

-0.6x

P/E Ratio

Is 0VY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0VY income statement (TTM)
Revenue	CN¥27.64m
Cost of Revenue	CN¥0
Gross Profit	CN¥27.64m
Other Expenses	CN¥1.49b
Earnings	-CN¥1.47b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-18.16
Gross Margin	100.00%
Net Profit Margin	-5,302.03%
Debt/Equity Ratio	1.7%

How did 0VY perform over the long term?

See historical performance and comparison

0VY Stock Overview

Rewards

Risk Analysis

I-Mab Competitors

XTRA:HPHA

€121.6m

XTRA:MDG1

€34.8m

XTRA:2INV

€54.0m

XTRA:BIO3

€1.4b

Price History & Performance

Recent News & Updates

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings released: CN¥16.53 loss per share (vs CN¥29.23 loss in FY 2022)

New minor risk - Financial data availability

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

Recent updates

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings released: CN¥16.53 loss per share (vs CN¥29.23 loss in FY 2022)

New minor risk - Financial data availability

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New major risk - Share price stability

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

First half 2022 earnings released: CN¥12.75 loss per share (vs CN¥14.67 loss in 1H 2021)

Less than half of directors are independent

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab Reportedly Exploring Possible Sale Amid Takeover Interest

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma At ASH 2021

I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease

I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors

I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

Investor sentiment deteriorated over the past week

I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of Its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe Covid-19

Investor sentiment deteriorated over the past week

I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio

I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus

I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥8.07 (vs CN¥463 loss in FY 2019)

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥8.07 (vs CN¥463 loss in FY 2019)

I-Mab to Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab At 2021 American Association for Cancer Research Annual Meeting

I-Mab to Report Fiscal Year 2020 Results on Mar 29, 2021

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency

I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors

I-Mab has completed a Follow-on Equity Offering in the amount of $177.3333 million.

I-Mab Announces Multiple Clinical Advancements of its Differentiated CD73 Antibody Uliledlimab in China and the U.S

I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China

New 90-day high: €51.00

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

New 90-day high: €37.60